Bayer Among Investors In $12M Funding For Edifice’s OTC Test For ‘Inflammatory Age’
Bayer led a $12m investment in Edifice Health, which plans to launch an OTC test kit to measure “inflammatory age” to help prevent chronic diseases. Consumer health R&D head Dave Evendon-Challis says the investment is in line with focus on deals for “big innovation jumps” in prevention.
You may also be interested in...
“If the previous decade was about the new digital, the current decade will require brands to undergo dynamic transformation,” said creative media consultant Kate Scott-Dawkins at NAD conference.
Bayer says its Consumer Health sales grew at twice the rate of the market in Q3, thanks to a number of operational changes instituted by business head Heiko Schipper back in 2018.
Acquisition of value-tier, female-first razor firm Billie, Inc. – previously attempted by P&G before the US Federal Trade Commission intervened – will add a youthful, on-message brand to the Schick owner’s women’s shave portfolio. The deal follows Edgewell’s bid to acquire Harry’s in 2020, also thwarted by the FTC.